Samsung Biologics Surpasses Annual Revenue of 4.5 Trillion Won... Operating Profit of 2 Trillion

Samsung Biologics achieved an annual revenue of 4.5 trillion won in 2025. It has been evaluated that the company has strengthened its position as a global top-tier contract development and manufacturing organisation (CDMO) with over 30% growth compared to the previous year.

Samsung Biologics announced on the 21st that it recorded an annual revenue of 4.557 trillion won and an operating profit of 2.0692 trillion won in 2025.

Thanks to the ramp-up of Plant 4, stable full operation of Plants 1 to 3, and positive exchange rate effects, revenue increased by 1.0599 trillion won and operating profit increased by 747.8 billion won compared to the previous year.

Samsung Biologics recorded a revenue of 1.2857 trillion won in the fourth quarter, achieving a high growth rate of over 35% compared to the same period last year. Operating profit was 528.3 billion won, an increase of 213.6 billion won compared to the same period last year. This is a result of increased product production due to the continued full operation of Plants 1 to 4.

In particular, Samsung Biologics continues to show a clear growth trend in orders. Last year, it signed three contracts worth over 1 trillion won, surpassing an annual order amount of 6 trillion won.

Since its establishment, the cumulative orders include 107 contract manufacturing (CMO) cases and 164 contract development (CDO) cases, with a total cumulative order amount reaching 21.2 billion dollars.

On this day, Samsung Biologics also emphasised that it has successfully implemented structural transformations and strategic investments for future growth over the past year. First, Samsung Biologics established a governance structure that allows it to focus more on the fundamental competitiveness of its CDMO business by successfully completing its spin-off. This analysis suggests that it has laid the groundwork to enhance corporate and shareholder value while resolving potential conflicts of interest and clearly transitioning to a 'pure CDMO' system.

In terms of production capacity expansion, the company has commenced full operation of its Plant 5 with a capacity of 180,000 litres and added a 1,000-litre bioreactor to Plant 2, expanding the total production capacity in Songdo (Plants 1 to 5) to 785,000 litres. When combined with the 60,000-litre capacity Rockville plant acquired last year, the global total production capacity is expected to expand to 845,000 litres.

Samsung Biologics expects to maintain a solid growth trend in 2026 based on strengthened competitiveness through pure CDMO, projecting a revenue growth of 15-20% compared to the previous year. This projection does not reflect the revenue contribution from the acquisition of the Rockville plant in the USA, and additional guidance will be provided after the acquisition is completed to reflect related performance.